| Contents | |
| 1 | The Pharmacology of Muscarinic Receptors |
| 1.1 | Introduction |
| 1.2 | Muscarinic receptor subtypes |
| 2 | Pharmacological Effects of Agonists and Therapeutic Applications |
| 2.1 | Cardiovascular system |
| 2.2 | Gastointestinal tract |
| 2.3 | Other smooth muscle |
| 2.4 | Glandular secretions |
| 2.5 | The eye |
| 2.6 | Central nervous system |
| 3 | Pharmacological Effects of Antagonists and Therapeutic Applications |
| 3.1 | Introduction |
| 3.2 | Cardiovascular system |
| 3.3 | Gastrointestinal tract |
| 3.4 | Urinary bladder |
| 3.5 | Airways |
| 3.6 | The eye |
| 3.7 | Prostate gland |
| 4 | The Medicinal Chemistry of Muscarinic Receptor Agonists and Antagonists |
| 4.1 | Scope |
| 5 | Muscarinic Agonists |
| 5.1 | Arecoline |
| 5.2 | Heterocyclic and other derivatives of arecoline |
| 5.3 | The synthesis of 1-aza-bicyclo[2.2.1]heptanes (1-azanorbornanes) and 1-azabicyclo[2.2.2]octanes (quinuclidines) |
| 5.3.1 | Intramolecular nucleophilic displacement by amines |
| 5.3.2 | Dieckmann condensation |
| 5.3.3 | Ester surrogates |
| 6 | Muscarinic Antagonists |
| 6.1 | Enantioselective synthesis of tertiary centres; tolterodine, rociverine, IQNP |
| 6.2 | Diels-Alder reactions |
| 6.2.1 | Indole alkaloids; allosteric activators of muscarinic binding |
| 6.2.2 | Himbacine; a muscarinic antagonist with allosteric properties |
| 6.2.3 | Cyclostellettamines; macrocyclic muscarinic antagonists |
| 7 | Conclusions and Future Prospects |
| 8 | References |